Thomas Stankovich - Nov 17, 2022 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
Chief Financial Officer
Signature
/s/ Thomas Stankovich
Stock symbol
RSLS
Transactions as of
Nov 17, 2022
Transactions value $
-$62,938
Form type
4
Date filed
12/20/2022, 03:35 PM
Previous filing
Nov 10, 2022
Next filing
Mar 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock, $0.001 par value per share Award $0 +365K +109.62% $0.00 698K Nov 17, 2022 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale -$61.8K -365K -52.29% $0.17 333K Nov 28, 2022 Direct F2
transaction RSLS Common Stock, $0.001 par value per share Sale -$778 -5.14K -1.55% $0.15 328K Dec 1, 2022 Direct F3
transaction RSLS Common Stock, $0.001 par value per share Sale -$334 -2.21K -0.68% $0.15 325K Dec 1, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were issued pursuant to a stock bonus granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.
F2 These shares were sold to cover taxes and fees in connection with the stock bonus.
F3 On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.